Formerly an employee of Thomson Healthcare.
The Estimation Power of Alternative Comorbidity Indices
Article first published online: 16 MAY 2008
© 2008, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Value in Health
Volume 11, Issue 5, pages 946–955, September/October 2008
How to Cite
Baser, O., Palmer, L. and Stephenson, J. (2008), The Estimation Power of Alternative Comorbidity Indices. Value in Health, 11: 946–955. doi: 10.1111/j.1524-4733.2008.00343.x
- Issue published online: 25 SEP 2008
- Article first published online: 16 MAY 2008
- health-care costs;
- regression analysis;
- risk adjustment
Objective: Health-care expenditures are strongly influenced by overall illness burden. Appropriate risk adjustment is required for correct policy analysis. We compared three risk adjustment methods: the Charlson comorbidity index (CCI), the chronic disease score (CDS), and the Agency for Healthcare Research and Quality's comorbidity index (AHRQCI) in terms of their estimation power in analyzing health-care expenditures.
Method: Data from the Thomson MarketScan® Research Databases (Thomson Healthcare, Ann Arbor, MI) were used to estimate total health-care expenditures of migraine patients treated by a triptan. Seven distinct multivariate models were evaluated for model fit (CCI only, CDS only, AHRQCI only, CCI + CDS, CCI + AHRQCI, CDS + AHRQCI, and CCI + CDS + AHRQCI). The estimation power of these indices (alone and in combination) was evaluated using Bayesian and Akaike information criteria, log-likelihood scores, and pseudo R2 values.
Results: Confirming results from previous studies, when comorbidity indices were considered individually the results were inconclusive. Statistically the best performance was observed in the model that included all three of the comorbidity measures (CCI + CDS + AHRQCI); however, the practical differences in the estimated values were small.
Conclusion: Low correlation between these comorbidity indices shows that it is possible to have potential risk factors that are not captured in the single comorbidity index. Each comorbidity measure considers different risks, and the collinearity of the three measures is not strong enough to preclude using them simultaneously in the same model.